Newsletter
| Promoter: | FDM | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| CNAT | No compensation | UNKNOWN |
| Max Profit: 0.82 % | Gain at close: 0.00 % |
April 10th, 2015
ARCO just went from $5.01 to $6.30, and now its time for my new pick (CNAT)
Symbol: CNAT
Price: 6:15
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.
Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease.
Emricasan is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis.
Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease.
For additional information, please visit www.conatuspharma.com
Sincerely,
FDM
Publisher, FDM
LEGAL DISCLAIMER: Neither http://integritysolutionir.com nor any of it's employees, contractors or officers are registered investmen.t advisors or a Broker/Dealer. As such, http://integritysolutionir.com does not offer or provide personalized investmen t advice. Although http://integritysolutionir.com employees and contractors may answer general customer service questions, they are not licensed under SECURITIES LAWS to address your particular investmen t situation. Nothing in this report, nor any communication by our employees or contractors to you should be considered personalized investmen t advice. You need to read our entire disclaimer written directly from our hired legal department at http://integritysolutionir.com/disclaimer/
Investing in securities is highly speculative and carries a great deal of risk. You may lose your entire investment. If you cannot afford to lose your entire investment do NOT invest in securities. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your FINANCIAL ADVISOR.
Why is this Disclaimer being provided?
Because we are paid to disseminate the Information to the public, we are required by the SECURITIES LAWS including Section 10(b) of the Securitie.s Exchang.e Ac.t of 1.9.3.4 and Rule 10b-5 thereunder, and Sectio.n 17(b) of the Securitie.s Ac.t of 1.9.3.3, as amended (the “Securitie.s Ac.t”), to specifically disclose certain information to you regarding our compensation as well as other matters including that we may hold, as well as purchase and sell the securities of a Profiled Issuer before, during and after we publish the Information about the Profiled Issuer. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer’s is set forth below under the heading captioned “What we were compensated”.
What we are not.
We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:* An INDEPENDENT ADVISOR or consultant;* Providing investmen.t advic.e; * Acting in the capacity of an investmen.t advise.r or engaging in activities that would be deemed to be providing investmen.t advic.e that requires registration either at the federal or state level;* Broker-dealer activities or acting in the capacity of a registered representative or broker;* Stock picker;* Securities trading expert;* Securities analyst; * FINANCIAL PLANNER or financial planning;* Provider of stock recommendations;* Provider of advice about buy and sell or hold recommendations as to specific securities; or* Making an offer or sale of securities or solicitation to purchase securities.
What conflicts of interest do we have in publishing the Information?
We are not objective or independent. Our activities involve actual conflicts of interest including:* We receive monetary and/or securities compensation in exchange for publishing favorable information about the Profiled Issuers; * We may own the Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from the open MARKET;* A short time after we acquire the Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information;* A third party shareholder compensating us may sell their shares of the Profiled Issuer while we are publishing favorable information about the Profiled Issuer.
We may hire third party service providers to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that these service providers publish.* By reading the Information you agree to indemnify and hold us harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information. Pursuant to a CONSULTING AGREEMENT "IntegritySolutionIr/ISI", which was not hired for a advertising arco, or CNAT beginning on 4/09/2015 ending 4/22/2015 disseminate information about arco, or orex, NO PAYMENT for compensation, and NO stock was bought or given as compensation for CNAT
READ ENTIRE Disclaimer --> http://integritysolutionir.com/disclaimer/
|
This message was sent to xxxxxx@gmail.com from: FDM | staff@fivedollarmovers.net | FDM / BTA | 100 New York Ave. | New York, New York 10001 |
Email Marketing by |
